| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03386929 2017-001455-32 Details | 2023-12-18 Interventional | 1/2 | 15 | Avelumab Axitinib Palbociclib Carcinoma, Non-… Lung Neoplasms Non-small Cell … Non-small Cell … | The SPRING trial had to be early terminated at the end of the Phase 1 portion of the study due
to the absence of funding necessary for the performance of the Phase 2. The trial was early terminated after the end of its Phase 1 due to lack of funding. As a result it was not possible to analyse the objectives of the study. | |||
| NCT03245658 Details | 2023-12-18 Interventional | 2 | [12 Refs] | 0 | Nabiximols Cachexia Marijuana Abuse Appetite Loss Cachexia; Cance… Cannabis Morbidity Mortality Neoplasms Pancr… Palliative Medi… | Organization was changed. The staff was relocated. - | ||
| NCT05999708 Details | 2023-12-15 Interventional | 1 | 0 | Indomethacin Colitis, Ulcera… | Study terminated prior to FSFV for strategic business reasons. - | |||
| NCT04939272 Details | 2023-12-15 Interventional | 1/2 | - | Venetoclax Lymphoma Lymphoma, Mantl… Recurrent Mantl… Refractory Mant… | FDA Clinical Hold - | |||
| NCT04798027 Details | 2023-12-15 Interventional | 1/2 | 182 | Vaccines COVID-19 | Sponsor's decision not to pursue further development of this product given the wide
availability of authorized/approved mRNA COVID-19 vaccines Due to early termination of this study by the Sponsor prior to full enrollment, the corresponding testing was not conducted, and few planned efficacy outcome measures data were not collected and analysis was not performed. | |||
| NCT03928314 Details | 2023-12-15 Interventional | 1 | 83 | Paclitaxel Solid Tumor | IND Withdrawn - | |||
| NCT04900038 Details | 2023-12-14 Interventional | 2 | 85 | Dolutegravir Lamivudine HIV Infections | Company decision to stop compound development. The decision was not based on any safety or
efficacy concerns. It reflected the company strategy for portfolio progression. - | |||
| NCT04115644 Details | 2023-12-14 Interventional | 4 | 82 | Bupivacaine Ketorolac Triamcinolone Triamcinolone A… Triamcinolone d… Triamcinolone h… Rotator Cuff In… Tendinopathy Full Thickness … Rotator Cuff Te… | Covid-19 and we failed to submit annual report for 2017 and 2018 - | |||
| NCT02387229 Details | 2023-12-14 Interventional | 3 | 1238 | Rivaroxaban Atrial Fibrilla… Ischemic Stroke ATRIAL FIBRILLA… | Consensus BRAIN-AF Executive Steering Committee to terminate. - | |||
| NCT05948462 Details | 2023-12-13 Interventional | 2 | 0 | Carboplatin Cisplatin Pemetrexed Carcinoma, Non-… Lung Neoplasms Lung Cancer Non-small Cell … | Study withdrawn by pharmaceutical funding partner - | |||
| NCT04745832 2020-004199-16 Details | 2023-12-13 Interventional | 3 | 82 | Bendamustine Hy… Cyclophosphamid… Prednisone Rituximab Vincristine Lymphoma Lymphoma, B-Cel… Lymphoma, Non-H… Follicular Lymp… Marginal Zone L… Non Hodgkin Lym… | Discontinuation of zandelisib program - | |||
| NCT04435782 2019-004783-22 Details | 2023-12-13 Interventional | 4 | 9 | Selexipag Familial Primar… Hypertension Pulmonary Arter… Ventricular Rem… | The Sponsor decided to prematurely terminate the study due to the lower-than-expected
recruitment rate. - | |||
| NCT05481489 Details | 2023-12-12 Interventional | 1 | 0 | Atropine Myopia | Due to sponsors convenience. - | |||
| NCT04899349 Details | 2023-12-12 Interventional | 2 | 2 | Dapagliflozin Fulvestrant Metformin Breast Neoplasm… Breast Cancer | Study was early terminated due to slow recruitment and emerging data showing that prophylactic
use of metformin may prevent or reduce the incidence of all-grades alpelisib-related
hyperglycemia. The decision was not driven by safety concerns - | |||
| NCT04848220 Details | 2023-12-12 Interventional | 2 | 29 | APD791 Microvascular O… | Business decision This study was terminated early due to a business decision that was not due to any safety concerns. The number of participants was smaller than originally planned and only summary statistics were therefore generated for primary and secondary outcome measures. | |||
| NCT04814433 Details | 2023-12-12 Interventional | 4 | 5 | Aminocaproic Ac… Bupivacaine Epinephrine Epinephryl bora… Lidocaine Racepinephrine Thrombin Tranexamic Acid Opioid Pain Med… | Both lack of enrollment as well as study staff turnover - | |||
| NCT04702789 Details | 2023-12-12 Interventional | 4 | 28 | Brimonidine Tar… Dorzolamide Latanoprost Timolol Glaucoma Glaucoma, Open-… Hypertension Ocular Hyperten… | For interests of sponsor. - | |||
| NCT03654989 Details | 2023-12-12 Interventional | 1/2 | 4 | Treprostinil Diabetic Foot Foot Ulcer Skin Ulcer Ulcer Diabetic Foot U… | recruitment difficulties - | |||
| NCT05665088 Details | 2023-12-11 Interventional | 3 | 13 | Dexmedetomidine Dementia Psychomotor Agi… Agitation | Study was terminated for business reasons; not due to safety or efficacy concerns - | |||
| NCT05425862 Details | 2023-12-11 Interventional | 1 | - | Talazoparib Prostatic Neopl… Metastatic Cast… | Enrolment suspended to further assess supplementary non-clinical study data. - |